DIIADDEPLT Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

bioactive research peptide compound Reference needs_revision Best effort · source review pending

Also known as: Pep19, WATACAP, white adipose tissue activator cyclophilin A peptide

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Components

Asp-Ile-Ile-Ala-Asp-Asp-Glu-Pro-Leu-Thr

Best-Effort Research Profile

DIIADDEPLT (Pep19) is a synthetically produced peptide with the amino-acid sequence Asp-Ile-Ile-Ala-Asp-Asp-Glu-Pro-Leu-Thr. It was developed by modifying the naturally identified cyclophilin A-derived peptide DITADDEPLT. Preclinical studies reported CB1-receptor inverse agonist activity, induction of uncoupling protein 1-related responses in adipocytes, and metabolic effects in diet-induced-obesity models. An early-stage placebo-controlled human study evaluated oral Pep19 capsules in adults with obesity; the compound remains investigational.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Administration Routes (Research)

oralin vitro

Reported Research Effects

Inverse agonist activity at cannabinoid type 1 receptors in receptor-binding studies.
Induction of uncoupling protein 1-associated responses and activation of ERK1/2 and AKT signaling in differentiated 3T3-L1 adipocytes.
Reduced adiposity and selected metabolic parameters in diet-induced-obese Wistar rats after oral administration.
In an early-stage human trial, oral 2 mg and 5 mg once-daily regimens were evaluated for 60 days; the publication reported changes in sleep-quality and body-composition endpoints, with limitations including small sample size, convenience sampling, and short duration.

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Reported research regimens include oral Pep19 at 100, 300, and 600 micrograms/kg in diet-induced-obese rats, and 1 mg/kg orally in mice for c-Fos evaluation. In vitro adipocyte experiments used approximately 0.1–10 micromolar, including 1 micromolar exposure for signaling studies. A 2025 early-stage human trial evaluated 2 mg or 5 mg oral capsules once daily at bedtime for 60 days. These are study-specific reference regimens, not recommendations. No reliable compound-specific half-life, onset time, solubility specification, or storage condition was identified in the authoritative sources reviewed.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

Amino-acid sequence: DIIADDEPLT; 10 residues; CAS Registry Number: 1536481-46-5; PubMed PMID: 29093454; PubMed PMID: 40450548; DOI: 10.1038/s41598-017-13690-9; DOI: 10.1002/dmrr.70056

Source-Backed Observations

The parent sequence DITADDEPLT was identified as a cyclophilin A-derived intracellular peptide, while DIIADDEPLT is described as a rationally modified sequence. Reported CB1 activity and metabolic findings are experimental and should not be interpreted as established clinical efficacy. Pep19 is distinct from other compounds also called Pep19, including antimicrobial peptide Pep19-2.5 and immunological epitope peptides.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

A novel peptide that improves metabolic parameters without adverse central nervous system effects
https://pubmed.ncbi.nlm.nih.gov/29093454/ (accessed 2026-10-16)

A novel peptide that improves metabolic parameters without adverse central nervous system effects
https://pmc.ncbi.nlm.nih.gov/articles/PMC5665932/ (accessed 2026-10-16)

Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults—Results From an Early-Stage Clinical Trial
https://pubmed.ncbi.nlm.nih.gov/40450548/ (accessed 2026-10-16)

Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults—Results From an Early-Stage Clinical Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC12126752/ (accessed 2026-10-16)

Peptide, pharmaceutical composition, CB receptor binder, method for modulating CB receptor function, use, method for treating obesity, and method for promoting aesthetic weight reduction in an individual
https://patents.google.com/patent/BR102012017421A2/en (accessed 2026-10-16)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.